| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 01/06/2005 | US20050002952 Proteinaceous antigen with 3-beta-(N-(N'-N'-dimethylaminoethane)carbamoyl)cholesterol; increasing immunogenicity |
| 01/06/2005 | US20050002945 Therapeutic and diagnostic conjugates for use with multispecific antibodies |
| 01/06/2005 | US20050002938 To screen for inhibitors of cell growth and to develop small molecule therapeutics for treating cancers |
| 01/06/2005 | US20050002918 Selective treatment of IL-13 expressing tumors |
| 01/06/2005 | US20050002901 Compositions and methods for treating coronavirus infection and SARS |
| 01/06/2005 | US20050002895 Methods and compositions for controlled release of drugs |
| 01/06/2005 | US20050002888 Water-in-silicone emulsions |
| 01/06/2005 | US20050002878 Use of tazarotene for preparing a nail varnish for treating and/or preventing psoriasis and nail varnish containing same |
| 01/06/2005 | US20050002865 Diagnostic/therapeutic agents |
| 01/06/2005 | US20050002860 Compositions comprising a tissue glue and therapeutic agents |
| 01/06/2005 | US20050000390 Low-viscosity opacifiers free from anionic surface-active agents |
| 01/06/2005 | CA2723328A1 Crystalline mesoporous oxide based materials useful for the fixation and controlled release of drugs |
| 01/06/2005 | CA2530364A1 Vaccines against group y neisseria meningitidis and meningococcal combinations thereof |
| 01/06/2005 | CA2530363A1 Carrier proteins for vaccines |
| 01/06/2005 | CA2529151A1 Chemical combination and method for increasing delivery of coenzyme q 10 |
| 01/06/2005 | CA2528067A1 Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli |
| 01/06/2005 | CA2527689A1 Recombinant anti-cd30 antibodies and uses thereof |
| 01/06/2005 | CA2526150A1 Treatment of humans with colloidal silver composition |
| 01/06/2005 | CA2525788A1 Anti-adhesion composites and methods of use thereof |
| 01/06/2005 | CA2521662A1 Methods and compositions for enhancing immune response |
| 01/06/2005 | CA2506821A1 Chemically-modified human growth hormone conjugates |
| 01/05/2005 | EP1493825A2 Method for producing nucleic acid ligands |
| 01/05/2005 | EP1493812A2 A truncated keratinocyte growth factor (KGF) having increased biological activity |
| 01/05/2005 | EP1493451A1 Hemostatic devices and methods of making same |
| 01/05/2005 | EP1493436A1 Compositions for parenteral administration and sustained-release of therapeutic agents |
| 01/05/2005 | EP1493433A1 Porous particles loaded with cosmetical or pharmaceutical active agents |
| 01/05/2005 | EP1493030A2 Charge-balanced chemoselective linkers |
| 01/05/2005 | EP1492876A1 Cationic amphiphiles for intracellular delivery of therapeutic molecules, composition, process and use thereof |
| 01/05/2005 | EP1492821A1 Iron dextrin compounds for the treatment of iron deficiency anaemia |
| 01/05/2005 | EP1492784A2 Substituted 2,3-diphenyl pyridines |
| 01/05/2005 | EP1492577A1 Film-forming compositions for protecting skin from body fluids and articles made therefrom |
| 01/05/2005 | EP1492569A1 Aqueous dispersible steryl ester compositions |
| 01/05/2005 | EP1492560A2 Use of interleukin-19 to treat cervical cancer |
| 01/05/2005 | EP1492538A1 Meloxicam suppositories containing e.g. polyethylenglycol |
| 01/05/2005 | EP1492532A1 Combinations of epinastine, belladonna and pseudoephedrine as new pharmaceutical formulations |
| 01/05/2005 | EP1492531A2 Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillin |
| 01/05/2005 | EP1492529A1 Oral administration of epothilones |
| 01/05/2005 | EP1492527A2 Process for preparing a finely self-emulsifiable pharmaceutical composition |
| 01/05/2005 | EP1492526A2 Improved prodrugs of cc-1065 analogs |
| 01/05/2005 | EP1492522A1 Ansamycin formulations and methods for producing and using same |
| 01/05/2005 | EP1492520A1 Pharmaceutical compositions |
| 01/05/2005 | EP1492514A1 A method for treating carrier particles and its use |
| 01/05/2005 | EP1492513A1 Hfa-suspension formulations containing an anticholinergic |
| 01/05/2005 | EP1492511A2 Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s) |
| 01/05/2005 | EP1492510A1 Low dose liquid entecavir formulations and use |
| 01/05/2005 | EP1492508A1 Controlled release dosage forms |
| 01/05/2005 | EP1492506A2 Matrix for sustained, invariant and independent release of active compounds |
| 01/05/2005 | EP1492505A2 Pharmaceutical preparation containing oxycodone and naloxone |
| 01/05/2005 | EP1492503A1 Stabilized natural cannabinoid formulation |
| 01/05/2005 | EP1492501A1 Methods of using lamellar bodies for therapeutic purposes |
| 01/05/2005 | EP1492500A1 Formoterol and ciclesonide aerosol formulations |
| 01/05/2005 | EP1492499A1 Formoterol and mometasone aerosol formulations |
| 01/05/2005 | EP1492498A2 Hfa-suspension formulation of an anhydrate |
| 01/05/2005 | EP1492452A2 System, formulation, kit and method for tagging colonic residue in an individual |
| 01/05/2005 | EP1492417A1 Encapsulated agglomeration of microcapsules and method for the preparation thereof |
| 01/05/2005 | EP1492410A1 Triglyceride fat |
| 01/05/2005 | EP1492409A2 Peptides with anti-hypertensive properties |
| 01/05/2005 | EP1441602A4 Molecular press dehydration method for vegetative tissue using the solid phase of water soluble polymer substances as a dehydrating agent |
| 01/05/2005 | EP1420643A4 Enhancement of transfection of dna into the liver |
| 01/05/2005 | EP1397386A4 Chimeric proteins for cell targeting and apoptosis induction and methods of using the same |
| 01/05/2005 | EP1255532B1 Osmotically-driven fluid dispenser |
| 01/05/2005 | EP1248630B9 Use of a dermatological composition containing oligosaccharides for the treatment of skin diseases |
| 01/05/2005 | EP1239837B1 Direct compression polymer tablet core |
| 01/05/2005 | EP1171134A4 Controlled release of sildenafil delivered by sublingual or buccal administration |
| 01/05/2005 | EP1109537B1 Immediate release oral formulation comprising peptide thrombin inhibitors and a combination of microcrystalline cellulose and sodium starch glycollate |
| 01/05/2005 | EP1073413B1 Methods and compositions for stabilizing acetylcholine compositions |
| 01/05/2005 | EP1032371B1 Polyethylene glycol matrix pellets for greasy, oily or sticky drug substances |
| 01/05/2005 | EP0996451B1 Triterpene saponin analogs having adjuvant and immunostimulatory activity |
| 01/05/2005 | EP0881891B1 Male contraceptive implant |
| 01/05/2005 | DE10328816A1 Implantierbare Stimulationselektrode mit einer Beschichtung zur Erhöhung der Gewebsverträglichkeit The implantable stimulation electrode having a coating to increase the tissue compatibility |
| 01/05/2005 | CN1561390A PEG-modified uricase |
| 01/05/2005 | CN1561387A Probiotic bifidobacterium strains |
| 01/05/2005 | CN1561344A Angiogenesis-inhibitory tripeptides, compositions and their methods of use |
| 01/05/2005 | CN1561343A Soluble T cell receptor |
| 01/05/2005 | CN1561233A Sanitary napkins with hydrophobic lotions |
| 01/05/2005 | CN1561232A Therapeutic agent comprising a B-subunit of a protein toxin |
| 01/05/2005 | CN1561230A Antigenic compositions |
| 01/05/2005 | CN1561214A New formulations and use thereof |
| 01/05/2005 | CN1561213A New formulations and use thereof |
| 01/05/2005 | CN1561210A Preparation of selective epoxide hydrolase II inhibitor |
| 01/05/2005 | CN1561209A Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
| 01/05/2005 | CN1561207A Therapeutic delivery of carbon monoxide |
| 01/05/2005 | CN1561205A Use of (R)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs |
| 01/05/2005 | CN1561203A Pharmaceutical salts |
| 01/05/2005 | CN1561202A Topical patch preparation containing a delayed-type hypersensitivity inducer and methods for using the same |
| 01/05/2005 | CN1561201A Pharmaceutical compositions comprising colloidal silicon dioxide |
| 01/05/2005 | CN1561200A Flashmelt oral dosage formulation |
| 01/05/2005 | CN1561199A Pharmaceutical composition comprising lipids comprising a polar and a nonpolar moiety |
| 01/05/2005 | CN1561198A Surfactant compounds and uses thereof |
| 01/05/2005 | CN1561165A Flavor-active peptides |
| 01/05/2005 | CN1560089A Compound of fluorinated carboxy alkyl cyclic starch gun ester kind and preparation process and application thereof |
| 01/05/2005 | CN1560003A Fluoroether compositions and methods for inhibiting their degradation in the presence of a lewis acid |
| 01/05/2005 | CN1559656A Preparation method of nucleous-shell type nanometer composite particle of magnetic micro particle and quantum point |
| 01/05/2005 | CN1559614A Dolysaccharide nanometer anticancer material and its preparation method |
| 01/05/2005 | CN1559613A Medicinal invert sugar injection |
| 01/05/2005 | CN1559534A Polylactic acid microglobule Chinese medicine compound for mula used for treating bone arthritis and its preparation method |
| 01/05/2005 | CN1559466A Traditional Chinese medicinal plaster |
| 01/05/2005 | CN1559433A Polyhexose type nanometer antimicrobial matter, prepn. method and use thereof |
| 01/05/2005 | CN1559421A Medicine compound contg. troxeration |
| 01/05/2005 | CN1559391A Volume-expansion protection agent, and application in treating blood-loss shock |